News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
547,894 Results
Type
Article (46314)
Company Profile (122)
Press Release (501447)
Multimedia
Podcasts (133)
Webinars (19)
Section
Business (145591)
Career Advice (2415)
Deals (28071)
Drug Delivery (135)
Drug Development (68447)
Employer Resources (156)
FDA (15926)
Job Trends (12044)
News (265254)
Policy (29880)
Tag
Academia (2307)
Academic (1)
Accelerated approval (27)
Adcomms (35)
Allergies (122)
Alliances (36146)
ALS (153)
Alzheimer's disease (1669)
Antibody-drug conjugate (ADC) (273)
Approvals (16005)
Artificial intelligence (447)
Autoimmune disease (126)
Automation (26)
Bankruptcy (312)
Best Places to Work (9193)
BIOSECURE Act (23)
Biosimilars (178)
Biotechnology (72)
Bladder cancer (147)
Brain cancer (52)
Breast cancer (545)
Cancer (4158)
Cardiovascular disease (372)
Career advice (2040)
Career pathing (38)
CAR-T (242)
CDC (59)
Cell therapy (666)
Cervical cancer (34)
Clinical research (58330)
Collaboration (1285)
Company closure (4)
Compensation (1040)
Complete response letters (64)
COVID-19 (2703)
CRISPR (81)
C-suite (642)
Cystic fibrosis (134)
Data (5312)
Decentralized trials (2)
Denatured (30)
Depression (124)
Diabetes (440)
Diagnostics (5479)
Digital health (31)
Diversity (6)
Diversity, equity & inclusion (43)
Drug discovery (193)
Drug pricing (200)
Drug shortages (33)
Duchenne muscular dystrophy (219)
Earnings (61872)
Editorial (60)
Employer branding (20)
Employer resources (141)
Events (81245)
Executive appointments (860)
FDA (18638)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (17)
Funding (1160)
Gene editing (178)
Generative AI (40)
Gene therapy (550)
GLP-1 (1011)
Government (4162)
Grass and pollen (8)
Guidances (369)
Healthcare (14869)
HIV (49)
Huntington's disease (44)
IgA nephropathy (78)
Immunology and inflammation (265)
Immuno-oncology (37)
Indications (68)
Infectious disease (2942)
Inflammatory bowel disease (174)
Inflation Reduction Act (13)
Influenza (97)
Intellectual property (201)
Interviews (453)
IPO (14110)
IRA (56)
Job creations (3170)
Job search strategy (1671)
Kidney cancer (16)
Labor market (75)
Layoffs (610)
Leadership (38)
Legal (7006)
Liver cancer (86)
Longevity (11)
Lung cancer (566)
Lymphoma (329)
Machine learning (36)
Management (52)
Manufacturing (629)
MASH (158)
Medical device (11508)
Medtech (11539)
Mergers & acquisitions (14857)
Metabolic disorders (1193)
Multiple sclerosis (133)
NASH (22)
Neurodegenerative disease (284)
Neuropsychiatric disorders (80)
Neuroscience (2735)
NextGen: Class of 2025 (4991)
Non-profit (3186)
Now hiring (26)
Obesity (590)
Opinion (269)
Ovarian cancer (135)
Pain (167)
Pancreatic cancer (184)
Parkinson's disease (249)
Partnered (25)
Patents (429)
Patient recruitment (370)
Peanut (52)
People (43894)
Pharmaceutical (33)
Pharmacy benefit managers (29)
Phase I (17488)
Phase II (25246)
Phase III (20709)
Pipeline (3683)
Policy (311)
Postmarket research (2210)
Preclinical (7116)
Press Release (28)
Prostate cancer (217)
Psychedelics (50)
Radiopharmaceuticals (231)
Rare diseases (756)
Real estate (4296)
Recruiting (64)
Regulatory (22666)
Reports (38)
Research institute (2103)
Resumes & cover letters (403)
Rett syndrome (23)
RNA editing (12)
RSV (70)
Schizophrenia (139)
Series A (201)
Series B (155)
Service/supplier (9)
Sickle cell disease (92)
Special edition (24)
Spinal muscular atrophy (135)
Sponsored (45)
Startups (2779)
State (1)
Stomach cancer (19)
Supply chain (97)
Tariffs (97)
The Weekly (102)
Vaccines (1044)
Venture capital (78)
Weight loss (422)
Women's health (59)
Worklife (21)
Date
Today (88)
Last 7 days (511)
Last 30 days (2201)
Last 365 days (28445)
2025 (28014)
2024 (31402)
2023 (34983)
2022 (45059)
2021 (48499)
2020 (45516)
2019 (36221)
2018 (27409)
2017 (27814)
2016 (25811)
2015 (27977)
2014 (21774)
2013 (17793)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (684)
Alabama (63)
Alaska (6)
Arizona (215)
Arkansas (10)
Asia (32121)
Australia (5625)
California (9594)
Canada (2357)
China (811)
Colorado (374)
Connecticut (430)
Delaware (280)
Europe (78451)
Florida (1449)
Georgia (295)
Hawaii (3)
Idaho (39)
Illinois (665)
India (44)
Indiana (402)
Iowa (20)
Japan (347)
Kansas (101)
Kentucky (24)
Louisiana (18)
Maine (71)
Maryland (1221)
Massachusetts (6997)
Michigan (249)
Minnesota (517)
Mississippi (5)
Missouri (110)
Montana (12)
Nebraska (20)
Nevada (105)
New Hampshire (59)
New Jersey (2622)
New Mexico (14)
New York (2511)
North Carolina (1261)
North Dakota (7)
Northern California (4673)
Ohio (253)
Oklahoma (14)
Oregon (31)
Pennsylvania (1880)
Puerto Rico (13)
Rhode Island (30)
South America (1039)
South Carolina (56)
South Dakota (1)
Southern California (3722)
Tennessee (142)
Texas (1417)
United States (33845)
Utah (247)
Virginia (223)
Washington D.C. (71)
Washington State (770)
West Virginia (4)
Wisconsin (94)
Wyoming (1)
547,894 Results for "pharmamar s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
December 11, 2025
·
1 min read
·
Annalee Armstrong
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal FDA safety review finds no confirmed pediatric deaths caused by COVID-19 vaccines, and Commissioner Marty Makary says no black box warning will be attached to the shots; and BioSpace looks at six biotechs that could be pharma’s next buy.
December 17, 2025
·
2 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Podcast
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts; and Novo Nordisk’s amycretin yields promising weight loss results.
December 3, 2025
·
1 min read
·
Heather McKenzie
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s Phase I/II studies of AMT-130 are “unlikely” to provide the primary evidence to support a biologics license application.
December 4, 2025
·
2 min read
·
Heather McKenzie
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
Biotech’s slump may finally be over in 2026. In interviews with
BioSpace
, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker
Alzheimer’s disease
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%
“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.
November 24, 2025
·
2 min read
·
Annalee Armstrong
Clinical research
5 of 2025’s Defining Clinical Wins
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal parts. Here are some of this year’s most glorious clinical trial victories.
December 15, 2025
·
9 min read
·
Tristan Manalac
Alzheimer’s disease
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point
After covering the Alzheimer’s space through every high and low,
BioSpace
’s Annalee Armstrong welcomes back Roche for the 2026 Alzheimer’s Renaissance.
December 2, 2025
·
2 min read
·
Annalee Armstrong
Regulatory
6 Biotechs With a Shot at the FDA’s Platform Technology Designation
After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.
November 21, 2025
·
9 min read
·
Tristan Manalac
1 of 54,790
Next